{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:48:14Z","timestamp":1790534894655,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Several clinical trials have shown that in patients with acute myocardial infarction (MI), statin therapy improves cardiovascular (CV) outcomes, but in these trials patients with acute heart failure (HF) were excluded or only a few were included. In patients with chronic HF, statin therapy does not reduce all-cause or CV mortality. We aimed to assess the association between statin therapy and clinical outcomes in the setting of acute HF with systolic dysfunction complicating acute MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a post-hoc analysis in 6632 patients included in the EPHESUS trial. The mean age of patients was 64 years and 71% were male. Overall, 47% of patients had a statin prescribed at baseline. Cox regression models and a secondary analysis using propensity score matching were fit to assess the association between statin prescription and clinical outcomes. During a mean follow-up of 16 \u00b1 7 months, all-cause death occurred in 385 (12%) patients with and in 647 (18%) patients without a statin (P &amp;lt; 0.001). After extensive adjustment, the risk of all-cause death was 20% lower in patients on statin [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.69\u20130.92, P = 0.001]. This positive association was mostly due to a lower risk of CV death (HR 0.76, 95% CI 0.65\u20130.88, P = 0.0002). In contrast, statin use was associated with a higher risk of non-CV hospitalizations (HR 1.16, 95% CI 1.02\u20131.33, P = 0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that patients with acute HF complicating acute MI may benefit from being on statin therapy. Prospective clinical trials are required to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs128","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T00:05:39Z","timestamp":1344384339000},"page":"221-227","source":"Crossref","is-referenced-by-count":12,"title":["Statin Therapy and Clinical Outcomes in Myocardial Infarction Patients Complicated by Acute Heart Failure: Insights from the EPHESUS Trial"],"prefix":"10.1093","volume":"15","author":[{"given":"Daniela","family":"Dobre","sequence":"first","affiliation":[{"name":"INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy \u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy \u00a0","place":["France"]},{"name":"INSERM U961 and Lorraine University , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Murin","sequence":"additional","affiliation":[{"name":"University of Bratislava \u00a0","place":["Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Parkhomenko","sequence":"additional","affiliation":[{"name":"University of Kiev \u00a0","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Lamiral","sequence":"additional","affiliation":[{"name":"INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy \u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[{"name":"Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"University of Groningen \u00a0","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Center of Clinical Investigation 9501, Lorraine Institute of Heart and Vessels Louis Mathieu, University Hospital Nancy \u00a0","place":["France"]},{"name":"INSERM U961 and Department of Cardiology, University Hospital Nancy, Lorraine University , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"2026011921140550700_ejhfhfs128-bib-0001","first-page":"1383","volume":"344","author":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","year":"1994","journal-title":"Lancet"},{"key":"2026011921140550700_ejhfhfs128-bib-0002","first-page":"1349","article-title":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","author":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","year":"1998","journal-title":"N Engl J Med"},{"key":"2026011921140550700_ejhfhfs128-bib-0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","year":"2002","journal-title":"Lancet"},{"key":"2026011921140550700_ejhfhfs128-bib-0004","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2026011921140550700_ejhfhfs128-bib-0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02201-4","article-title":"Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial","volume":"89","author":"Cannon","year":"2002","journal-title":"Am J Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1161\/01.CIR.0000137828.06205.87","article-title":"Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study","volume":"110","author":"Pasceri","year":"2004","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-0007","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.106.621763","article-title":"Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study","volume":"114","author":"Patti","year":"2006","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-0008","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"2026011921140550700_ejhfhfs128-bib-0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2006.07.106","article-title":"Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT","volume":"119","author":"Krum","year":"2007","journal-title":"Int J Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00011","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(02)01827-2","article-title":"Statins and chronic heart failure: do we need a large-scale outcome trial?","volume":"39","author":"Krum","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00012","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00013","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026011921140550700_ejhfhfs128-bib-00014","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026011921140550700_ejhfhfs128-bib-00016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2125.2006.02769.x","article-title":"Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?","volume":"63","author":"Dobre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2026011921140550700_ejhfhfs128-bib-00017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2026011921140550700_ejhfhfs128-bib-00018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archinte.1994.00420040081012","article-title":"Modifiable risk factors for incident heart failure in the coronary artery surgery study","volume":"154","author":"Hoffman","year":"1994","journal-title":"Arch Intern Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00019","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1054\/jcaf.2002.0804216","article-title":"Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure","volume":"8","author":"Horwich","year":"2002","journal-title":"J Card Fail"},{"key":"2026011921140550700_ejhfhfs128-bib-00020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/archinte.1993.00410090025004","article-title":"Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data","volume":"153","author":"Kronmal","year":"1993","journal-title":"Arch Intern Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00021","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2003.11.039","article-title":"Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure","volume":"43","author":"Kalantar-Zadeh","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00022","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199502233320802","article-title":"The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion","volume":"332","author":"Anderson","year":"1995","journal-title":"N Engl J Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.0000084539.58092.DE","article-title":"Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy","volume":"108","author":"Node","year":"2003","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-00024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM199502233320801","article-title":"Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease","volume":"332","author":"Treasure","year":"1995","journal-title":"N Engl J Med"},{"key":"2026011921140550700_ejhfhfs128-bib-00025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2011","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-00026","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1161\/01.CIR.99.22.2871","article-title":"Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis","volume":"99","author":"Baller","year":"1999","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-00027","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.99.4.475","article-title":"Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin","volume":"99","author":"Guethlin","year":"1999","journal-title":"Circulation"},{"key":"2026011921140550700_ejhfhfs128-bib-00028","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cardiores.2006.04.011","article-title":"Statins in the treatment of chronic heart failure: biological and clinical considerations","volume":"71","author":"van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ","year":"2006","journal-title":"Cardiovasc Res"},{"key":"2026011921140550700_ejhfhfs128-bib-00029","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjcard.2009.10.021","article-title":"Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study)","volume":"105","author":"van der Harst P, Slart RH, Tio RA, Dunselman PH, Willemsen AT, van den Heuvel AF, Voors AA, van Veldhuisen DJ","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2026011921140550700_ejhfhfs128-bib-00031","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","article-title":"Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis","volume":"105","author":"Alberton","year":"2012","journal-title":"QJM"},{"key":"2026011921140550700_ejhfhfs128-bib-00032","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2026011921140550700_ejhfhfs128-bib-00033","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0735-1097(02)02379-3","article-title":"Outpatient adherence to beta-blocker therapy after acute myocardial infarction","volume":"40","author":"Butler","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011921140550700_ejhfhfs128-bib-00034","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2004.01.041","article-title":"Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge","volume":"43","author":"Butler","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfs128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfs128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/2\/221\/66440836\/eurjhf_15_2_221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/2\/221\/66440836\/eurjhf_15_2_221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:16:37Z","timestamp":1768875397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/2\/221\/8428630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,27]]},"published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs128","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,2]]},"published":{"date-parts":[[2013,2,1]]}}}